Kim Branson

Senior Vice President and Global Head of Artificial Intelligence and Machine Learning at GSK, leading a global team of engineers, data scientists and machine learning researchers pioneering a more data-driven approach to improve drug discovery.I'm passionate about modeling, machine learning and in particular the application of deep learning methods in drug development. At GSK.ai we’re unlocking the potential of complex genetic data, using the team’s cross-discipline expertise and collaborating with leading partners make better predictions and to speed up delivery of next generation medicines and vaccines to patients – at scale. By bringing together leading science, unique technology, and outstanding people we are aiming to double our development success rate to make a difference to more patients’ lives.My previous work, has included large-scale machine learning and medical informatics initiatives across a range of ventures from computational drug design to disease risk prediction.

Tuesday
May 06
Strategic Alliances: How Pharma Thinks About Computational Drug Discovery Partnerships
2:25 PM

-

2:55 PM

This session explores how pharma companies approach and build effective partnerships with computational drug discovery firms. Industry experts will share insights on best practices for data sharing, strategies for navigating cultural challenges with AI-driven startups, and the role of explainable AI in fostering trust. The discussion will also cover common mistakes AI biotech companies make when approaching pharma and the considerations around using proprietary algorithms versus open-source models to advance drug discovery.

Conference Pass

2,495

USD

Keynotes & Firesides

Workshops & Breakouts

1:1 Partnering App

Meals & Receptions

Session Recordings

Until Friday April 18th

Full Rate:

$3,495

Other Speakers

Copyright SynBioBeta 2025